For a patient with atopic dermatitis who is ready for systemic therapy, the first priority is getting them on one, Raj Chovatiya, MD, PhD, MSCI, told Dermatology Times in an interview at. “There ...
The recent FDA approval of remibrutinib (Rhapsido) for symptomatic dermographism (SD) gives clinicians an on-label option for a condition long managed with off-label therapies, Raj Chovatiya, MD, PhD, ...
No skin lesion flares occurred through 16 weeks after patients with an inadequate response to dupilumab switched, and itch ...
Personalized prescription skin care is not necessarily designed around a single diagnosis or endpoint. As patients’ skin changes, their treatment goals may shift as well—from ...
Shannon Trotter, DO, discusses augmented intelligence in skin cancer detection, the approval of remibrutinib for symptomatic ...
In a recent interview with Dermatology Times, Whitney Tolpinrud, MD, board-certified dermatologist and chief dermatologist at Curology, discussed the evolution of personalized prescription dermatology ...
Upadacitinib showed broader inflammatory effects and earlier skin barrier restoration than dupilumab in atopic dermatitis. “Skin biopsies from the head-to-head Level Up study showed broader effects on ...
The supplemental New Drug Application seeks to expand the use of Ameluz with red light photodynamic therapy beyond the face and scalp to actinic keratoses on the extremities, neck, and trunk.
The National Eczema Association (NEA) has released the State of AD 2026 National Indicator Report, a Milliman analysis ...
Once-daily oral icotrokinra produced sustained plaque psoriasis control through week 112, including scalp, genital, ...
Tenesha Wallace Hood, MA, of the National Eczema Association (NEA), reviews how state-level data from the NEA's State of AD 2026 National Indicator Report can inform access to atopic dermatitis care.
Nearly 95% of assessed TikTok “glass skin” videos contained potentially misleading claims, with none citing external references and none produced by dermatologists.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results